Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
NCT06678230
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Anlotinib
Sponsor
The First Hospital of Jilin University